fbpx

Weekly Top News – IBD – September 30, 2019

September 30, 2019

Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
RedHill Biopharma provides H2/2019 R&D update (GlobeNewswire) – Sep 26, 2019 – “…the last patient enrolled in the open-label extension Phase 3 study with RHB-104 in Crohn’s disease (MAP US2 study) has recently completed their participation in the study. A total of 30 subjects completed 52 weeks of treatment with RHB-104 in the MAP US2 study, with top-line results expected in the fourth quarter of 2019.”

 

etrasimod (APD334) / Arena
Arena Pharmaceuticals presented new data from the phase 2 OASIS trial for etrasimod at the World Congress of Gastroenterology Meeting (PRNewswire) – Sep 26, 2019 – P2, N=156; OASIS (NCT02447302); Sponsor: Arena Pharmaceuticals; “Arena Pharmaceuticals, Inc…presented new data from the Phase 2 OASIS trial for etrasimod…in development for a range of immune-mediated and inflammatory conditions…These data were presented at the World Congress of Gastroenterology Meeting in Istanbul, Turkey. ‘Steady-state etrasimod trough concentrations were achieved and maintained from weeks 1 to 12 in patients with moderately to severely active ulcerative colitis….”

 

Humira (adalimumab) / Eisai, AbbVie; Remicade (infliximab) / Mitsubishi Tanabe, J&J
Micro‐fragmented autologous adipose tissue injection for fistula‐in‐ano (MAATIFA) in patients with Crohn’s disease: a prospective observational study (ESCP 2019) – Sep 28, 2019 – Abstract #P453; “Results Ten patients underwent the procedure in the time interval between two biologic drug administration (6 infliximab –4 adalimumab). Conclusion Micro-fragmented autologous adipose tissue injection showed promising results in promoting Crohn’s-related complex anal fistula healing. These good results are probably related to the reduction of inflammation and the activation of a reparative mechanisms.”

 

Xeljanz (tofacitinib) / Pfizer
Xeljanz sales projection: $2.2B in 2019, $3B in 2020 and $4.1B in 2024 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 725; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Simponi WW sales projection: $3B in 2019 and $3.7B in 2024 (Cowen & Co) – Sep 26, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 2876; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Humira (adalimumab) / Eisai, AbbVie
Humira patent protection: Until 2022-2034 (Cowen & Co) – Sep 28, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 2872; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Health Care Research, et al; DATE: 09/17/2019

 

mirikizumab (LY3074828) / Eli Lilly
Phase 3 initiation of mirikizumab, a candidate drug for the treatment of immune diseases, for patients with moderate and severe active Crohn’s disease [Google Translation] (Newsmp) – Sep 24, 2019 – “Lilly Korea will conduct a phase 3 clinical trial of a candidate drug for treating immunological diseases in patients with Crohn’s disease in Korea. The Ministry of Food and Drug Safety approved the phase 3 trial of Mirikizumab…filed by Lilly Korea.”

 

Stelara (ustekinumab) / J&J
Stelara WW sales projection: $6.2B in 2019, $7B in 2020 and $10B in 2024 (Cowen & Co) – Sep 26, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 2917; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Humira (adalimumab) / Eisai, AbbVie
Humira patent expiry: January 2023 (Cowen & Co) – Sep 23, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 715; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Entyvio (vedolizumab) / Takeda
Limit therapies [Google Translation] (Nasz Dziennik) – Sep 23, 2019 – “Crohn patients are also waiting for the drug vedolizumab (Entyvio) used in many EU countries. In the message sent to us, the Ministry of Health ensures that the specific product will soon be available in Poland. ‘Entyvio (vedolizumab) will be reimbursed from November 1, 2019 as part of a drug program for the treatment of severe, active Crohn’s disease as another therapeutic option in addition to infliximab and adalimumab,’ reads the letter.”

No Comments

Post a Comment

Comment
Name
Email
Website